DDA Recalls Substandard Batch of Pediatric Amoxicillin Clavulanate Suspension
Regulatory Updates

DDA Recalls Substandard Batch of Pediatric Amoxicillin Clavulanate Suspension

PHU Scientific Desk October 1, 2026 1 min read
Save

Immediate market quarantine ordered for Batch #AMX-2026-B94 following assay failure and dissolution non-compliance detected at National Medicine Laboratory testing checkpoints.

Summary

Immediate market quarantine ordered for Batch #AMX-2026-B94 following assay failure and dissolution non-compliance detected at National Medicine Laboratory testing checkpoints.

Source & reference

  • Issuing organization: Department of Drug Administration
  • Published: 18 Oct 2026
  • Notice type: Safety Alert
  • Document: Recall Notice (available from the issuing organization)

Curated by the PHU Scientific Desk from the official circular. The full official document is available from the issuing organization.

Batch Recall Pharma Vigilance
Save
Share this
X WhatsApp Telegram LinkedIn
Back to all news

Related Articles

WHO Releases Consolidated Guidelines on Tuberculosis Preventive Treatment 2026
WHO Clinical Guidelines

WHO Releases Consolidated Guidelines on Tuberculosis Preventive Treatment 2026

Expanded recommendations highlighting shortened 1-month rifapentine-plus-isoniazid (1HP) regimens for household contacts of bacteriologically confirmed pulmonary TB, pediatric dosing tables, and…

Oct 1, 2026
National Health Insurance Board Expands Primary Care Package Coverage in 25 Mountain Districts
Health Systems

National Health Insurance Board Expands Primary Care Package Coverage in 25 Mountain Districts

Revision doubles catastrophic illness caps for oncology and dialysis, introduces telemedicine reimbursement codes, and subsidizes 100% premium contributions for ultra-poor…

Oct 1, 2026
NHRC Issues Updated National Ethical Guidelines for Biomedical Research Involving Human Participants
Regulatory Updates

NHRC Issues Updated National Ethical Guidelines for Biomedical Research Involving Human Participants

Comprehensive revisions introducing stringent bio-banking sovereignty stipulations, mandatory pediatric assent mechanisms, digital informed consent guidelines, and institutional oversight protocol updates.

Oct 1, 2026